申请人:Janssen Pharmaceutica N.V.
公开号:US05607932A1
公开(公告)日:1997-03-04
The invention is concerned with the compounds having the formula ##STR1## the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Y is CH or N; R.sub.1, R.sup.2 and R.sup.3 each independently are hydrogen or C.sub.1-4 alkyl; R.sup.4 and R.sup.5 each independently are hydrogen, halo, C.sub.1-4 alkyl, C.sub.1-4 alkyloxy, hydroxy, trifluoromethyl, trifluoromethyloxy or difluoromethyloxy; R.sup.6 is pyridinyl optionally substituted with up to two C.sub.1-4 alkyl groups; di(C.sub.1-4 alkyl) hydroxypyridinyl; di(C.sub.1-4 alkyl)C.sub.1-4 alkyloxypyridinyl; pyridazinyl optionally substituted with C.sub.1-4 alkyloxy; pyrimidinyl optionally substituted with hydroxy or C.sub.1-4 alkyloxy; thiazolyl optionally substituted with C.sub.1-4 alkyl; thiadiazolyl optionally substituted with C.sub.1-4 alkyl; benzoxazolyl or benzothiazolyl; or R.sup.6 is pyrazinyl or pyridazinyl substituted with C.sub.1-4 alkyl; Z is C.dbd.O or CHOH; and ##STR2## is a radical of formula ##STR3## Compositions comprising said compounds, processes for preparing the same and the use of these compounds as a medicine.
本发明涉及具有以下式子的化合物,其药学上可接受的加成盐和立体化学异构体,其中Y为CH或N;R1,R2和R3各自独立地为氢或C1-4烷基;R4和R5各自独立地为氢,卤素,C1-4烷基,C1-4烷氧基,羟基,三氟甲基,三氟甲氧基或二氟甲氧基;R6为吡啶基,可选地带有最多两个C1-4烷基基团;双(C1-4烷基)羟基吡啶基;双(C1-4烷基)C1-4烷氧基吡啶基;嘧啶基,可选地带有羟基或C1-4烷氧基;噻唑基,可选地带有C1-4烷基;噻二唑基,可选地带有C1-4烷基;苯并噁唑基或苯并噻唑基;或R6为带有C1-4烷基的吡嗪基或嘧啶基;Z为C = O或CHOH;以及##STR2##是公式##STR3##的基团。包含这些化合物的组合物,制备这些化合物的过程以及这些化合物作为药物的用途。